On January 26, the information released by the National Drug Administration (NMPA) showed that Smeaglutide Tablets under Novo Nordisk (China) Pharmaceutical Co., Ltd. was approved for listing to treat type 2 diabetes. This is the first domestically approved oral GLP-1 (glucagon like peptide-1) receptor agonist.